Pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, is indicated for the treatment of type 2 diabetes. Pioglitazone undergoes hepatic metabolism by cytochrome P450 2C8 (CYP2C8) and interindividual variability exists in pioglitazone disposition and response. In previous analyses, it has been shown that the CYP2C8*3 polymorphism significantly impacts pioglitazone pharmacokinetics in humans. The purpose of this investigation was to develop a population pharmacokinetic model using nonlinear mixed effects analysis to evaluate and quantify the effect of CYP2C8*3, demographic, and clinical variables on interindividual variability in pioglitazone pharmacokinetics in nondiabetic adults. Data were obtained from 31 healthy volunteers (n=16 CYP2C8*1/*1, n=15 CYP2C8*3 carriers) who had previously participated in the monotherapy phase of a pioglitazone drug-drug interaction study. Participants received a single 15 mg dose of pioglitazone followed by a 48-h sampling period. A two-compartment model with first order absorption and elimination (Akaike Information Criteria (AIC)=2889) showed a better fit for pioglitazone than a one-compartment model (AIC=3008). Covariate analysis revealed that CYP2C8*3 had a significant effect on pioglitazone central compartment clearance (CL/F; p=0.0005) and intercompartmental clearance (Q/F; p=0.004). Pioglitazone CL/F and Q/F were 52% and 286% higher, respectively, in carriers of the CYP2C8*3 allele than in CYP2C8*1 homozygotes. Furthermore, inclusion of CYP2C8*3 as a covariate on CL/F and Q/F decreased interindividual variability in these parameters by 5.2% and 14%, respectively. Other variables (e.g., sex, body weight) were not significant covariates on pioglitazone pharmacokinetics in the model. In summary, CYP2C8*3 significantly affected pioglitazone CL/F, Q/F, and interindividual variability in these parameters in this healthy volunteer cohort.
modeling Pioglitazone, a thiazolidinedione peroxisome proliferatoractivated receptor-γ agonist, improves insulin sensitivity and is used for the treatment of type 2 diabetes. 1) Pioglitazone has also been shown to substantially reduce the risk of developing type 2 diabetes in patients with impaired glucose tolerance (i.e., prediabetes). 2) In terms of clinical pharmacology, pioglitazone is administered in doses of 15 to 45 mg once daily. The drug is hepatically metabolized by cytochrome P450 2C8 (CYP2C8), and to a lesser extent by CYP3A4, CYP1A2, CYP2C9 and CYP2D6. [3] [4] [5] [6] [7] M-III (keto-derivative) and M-IV (hydroxyl/derivative) are the main circulating active metabolites of pioglitazone in humans.
3) Pioglitazone is well-absorbed after oral administration with a mean absolute bioavailability of 83% and a T max of 0.5 to 3 h. The drug is highly protein bound (>99%) and the volume of distribution ranges from 0.2 to 0.3 L/kg. The mean apparent oral clearance is 2.4 L/h and the terminal elimination half-life is about 9 h. 3) Interindividual variability exists in pioglitazone disposition and response, and some of this variability is due to genetic polymorphisms. 8) In terms of drug metabolism, Tornio and colleagues were the first to show that the polymorphic CYP2C8*3 allele (Arg139Lys, Lys399Arg) is associated with increased pioglitazone metabolism in humans. 9) Specifically, CYP2C8*3 carriers had lower pioglitazone plasma exposure and a higher rate of metabolite formation than subjects with the wild-type CYP2C8*1/*1 genotype. 9) Consistent with these data, we recently reported in healthy volunteers that pioglitazone plasma exposure was lower and weight-adjusted oral clearance was higher in CYP2C8*3 carriers as compared with wild-type homozygotes. 10) An understanding of factors that govern interindividual variability in pioglitazone pharmacokinetics, whether it is due to genetic polymorphisms or demographic or clinical variables, is important given that clinical response and adverse effects (e.g., weight gain) are influenced by pioglitazone plasma concentrations.
Few published pioglitazone studies have used population pharmacokinetic methods in their analyses. Population pharmacokinetic compartmental modeling is advantageous because it allows for the identification and quantification of the sources and correlates of interindividual variability in drug disposition in a population. 11, 12) As such, the purpose of this investigation was to develop a population pharmacokinetic model using nonlinear mixed effects analysis with NONMEM to evaluate and quantify the effects of CYP2C8*3, demographic, and clinical variables on interindividual variability in pioglitazone pharmacokinetics in healthy, Caucasian, nondiabetic adults.
MATERIALS AND METhODS
Study Design and Population Data for this population pharmacokinetic analysis were obtained from the pioglitazone monotherapy phase of our previous study, which evaluated the impact of the CYP2C8*3 allele on the drug-drug interaction between pioglitazone and gemfibrozil. The detailed methods and results of this parent study have been previously published. 10) Briefly, 31 healthy Caucasian volunteers (21 women and 10 men) between 21 to 60 years of age took part in the pioglitazone monotherapy phase of the parent study. The participants were prospectively screened and enrolled based on CYP2C8 genotype (n=16 CYP2C8*1/*1, n=14 CYP2C8*1/*3, and n=1 CYP2C8*3/*3). CYP2C8 genotyping was conducted using PCR-pyrosequencing analysis, as previously described. 10, 13) The pharmacokinetic study took place on the University of Colorado Clinical and Translational Research Center Inpatient Unit. After an overnight fast, all participants received a single 15 mg dose of pioglitazone by mouth at 09:00 a.m. Serial blood samples were collected for pioglitazone plasma concentrations pre-dose and 1, 2, 3, 4, 5, 7, 9, 12, 18, 24, and 48 h post-dose. Pioglitazone plasma concentrations were measured using a validated LC/MS assay. 10) Participants received a standardized breakfast (600 calories; 55% carbohydrates, 15% protein, and 30% fat) two hours after the pioglitazone dose. The parent study was approved by the Colorado Multiple Institutional Review Board, and all participants provided written, informed consent.
Population Pharmacokinetic Analysis Population pharmacokinetic analysis was performed by nonlinear mixed effects modeling using NONMEM ® software, version 7.2.0, (ICON Development Solutions, Ellicott City, Maryland, U.S.A.) with first order conditional estimation with η-ε interaction (FOCE-I). All statistical and graphical analyses were performed using PDx-Pop™ (ICON Development Solutions, Ellicott City, Maryland, U.S.A.). For the base structural model, one-and two-compartment models with first order absorption and elimination were tested using the NONMEM subroutines ADVAN2/TRANS2 and ADVAN4/TRANS4. The one-compartment model was parameterized on clearance (CL/F, L/h), volume of distribution (V/F, L), and the absorption rate constant (K a , h
−1
). The two-compartment model was
). For nonhierarchical models, selection of the best model was guided by goodness-of-fit criteria including visual observation of predicted and observed data fit, diagnostic scatter plots, precision of parameter estimates, and statistical criteria including reduction in the objective function value (OFV) and the Akaike Information Criteria (AIC) value.
Between-subject variability was described using an exponential error model according to the equation: P i = P TV ×exp(η i ), where P i is the value of the parameter in the i-th individual; P TV is the value of the parameter in a typical individual; and η i is the difference between P i and P TV , which has a mean of 0 and a variance of ω 2 .
14) The % coefficient of variation (%CV) was calculated as the square root of ω 2 multiplied by 100. Residual unexplained variability was also described using an exponential error model, with a variance of σ 2 . The % coefficient of variation (%CV) was calculated as the square root of σ 2 multiplied by 100. Covariate Analysis Following development of the base structural model, covariate analysis was performed for the following variables: CYP2C8 genotype, sex, body weight, body mass index, age, serum creatinine, and liver function tests. An initial screening of the associations between these variables and pharmacokinetic parameters was conducted by visual graphical inspection of the individual random effects as well as screening of covariates using general additive model (GAM) analysis (decrease in AIC value). Categorical covariates were modeled using an additive effect (e.g., TVCL=θ 1 +θ 6 *CYP2C8, where the CYP2C8*1/*1 genotype was coded as 0, and the CYP2C8*3 allele was coded as 1). Continuous covariates were incorporated as linear, exponential or power functions. The potential covariates selected from the initial screening were entered into the covariate model. A stepwise forward selection and backward deletion approach was utilized, whereby one covariate was added and deleted at a time. A significant covariate was selected to be retained in the full model if the addition of that covariate resulted in a decrease in the OFV greater than 3.84 (p<0.05) during forward selection, and if removal of that covariate resulted in an increase in OFV greater than 7.88 (p<0.005) during backward elimination. Along with a significant reduction in OFV, the reduction in AIC value, the reduction in interindividual variability [% coefficient of variation (%CV)] and the increase in the precision of the variable estimates [% relative standard error (%RSE)] were used as indicators for improvement in the goodness-of-fit.
Model Evaluation
The evaluation of the final population pharmacokinetic model was performed using visual predictive check and bootstrap analysis using PDx-Pop™. For visual predictive check, Monte Carlo simulations of the original data set were generated using the final population pharmacokinetic model, where each subject's covariates, sampling times, and dosing histories were used 100 times. Model adequacy was determined by comparing the distribution of the median concentration of the observed data with 5th and 95th percentiles of the simulated data using exploratory graphs.
Nonparametric bootstrap analysis was performed to validate the robustness, stability, and reliability of the final selected population pharmacokinetic model. The final model was fitted to each of 1000 bootstrap datasets. The arithmetic means of parameter estimates, %RSE, and 95% confidence intervals (CI) were calculated and compared with the parameter estimates obtained from the final selected pharmacokinetic model.
RESULTS

Population Data
The pioglitazone pharmacokinetic database consisted of 31 healthy Caucasian subjects and 351 plasma concentrations. A summary of the baseline characteristics for the study population is presented in Table 1 . Observed and model-predicted plasma concentration-time profiles for pioglitazone are shown in Fig. 1 .
Base Structural Model Development A base structural model, without covariates, was developed for pioglitazone using 351 plasma concentrations in the pharmacokinetic database. A summary of base model development and the associated improvement in OFV is shown in Table 2 . Model development began with a simple one-compartment model with first order absorption and elimination. Subsequent distribution compartments were added to improve the goodness-of-fit. The addition of a lag time component to the one-compartment and two-compartment models did not show any improvement in goodness-of-fit, which is likely due to limited early pharmacokinetic data points. Visual inspection of observed and model predicted plasma concentration-time plots, diagnostic plots (weighted residuals versus time profile plots), and change in AIC (−133) and OFV (−136.6; p=<0.0001) showed that a two-compartment model (AIC= 2889) with first order absorption and elimination provided a better fit with the observed data than a one-compartment model (AIC= 3022) (Fig.  1, Table 2 ). During covariate analysis, high interindividual variability in V p /F resulted in negative 95%CI values and difficulties with model convergence. In order to overcome these problems, V p /F was fixed to the mean value obtained from the base model. Furthermore, due to limited time points in the absorption phase (first sampling time point was 1 h, which was close to the observed T max ), the accurate estimation of K a was problematic; thus, covariates were not evaluated on K a . A summary of the mean parameter estimates and %RSE for the base model of pioglitazone is summarized in Table 3 .
Covariate Analysis A summary of covariate model development using forward selection methods is shown in Table  2 . The process of initial covariate screening showed a significant effect of CYP2C8*3 and BMI on CL/F, V c /F and Q/F. In contrast, the effects of other covariates such as sex, creatinine clearance, and liver function on CL/F, V c /F and Q/F were not significant during the initial screening. As such, these covariates were not included in full model development or in Table  2 . In full model development, inclusion of CYP2C8 genotype as a covariate on CL/F and Q/F showed a statistically significant reduction in OFV (p<0.005), whereas inclusion of BMI as a covariate did not result in a reduction in the OFV≥3.84 ( Table 2 ). The final model parameters are shown in Table 3 and can be described as follows: 
. Plots of between-Subject Random Effects of CYP2C8*3 on CL/F and Q/F for Pioglitazone
In the box plots of categorical covariates, the black circle in the box plot represents the median, while the top and bottom of the box represent the first and third quartiles, respectively. ETA1 is an interindividual random effect on CL/F, and ETA3 is an interindividual random effect on Q/F. The black line at y=0 is included as a reference. 
Fig. 4. Visual Predictive Check of Pioglitazone
The visual predictive check included 100 predictions using model parameters for the final model by the FOCE-I method. The blue thick dotted line is the 95% confidence interval, the green dotted line is the 90% prediction confidence interval, the solid black line is the median line, and the open circles are observed data points. The percentage of observations outside the 90% prediction confidence interval was 11.8%.
as a covariate on CL/F and Q/F reduced the between-subject variability by 5.2% and 14%, respectively (Table 3 ). The amount of residual unexplained variability in the final model was 15.4%.
Model Evaluation Goodness-of-fit plots for the final selected model showed that the final population pharmacokinetic model adequately describe the data (Fig. 3) . As presented in Fig. 3, weighted residuals (WRES) versus time plots showed a random distribution without any particular pattern of distribution, and most of the data points were between WRES of ±2. Observed (DV) versus individual model predicted (IPRE) plots also showed the distribution of the data points to be near the line of unity (Fig. 3) . Final population pharmacokinetic models were evaluated for robustness, stability, and reliability using visual predictive check and bootstrap analysis by re-sampling strategies. Visual predictive checks confirmed the adequacy of models; less than 13% of observations were outside the 90%CI (Fig. 4) . During nonparametric bootstrap analysis, a total 875 runs minimized successfully out of 1001 attempts. The results for the bootstrap analysis containing the arithmetic mean and %RSE are summarized in Table 3 , along with the best-fit final model.
DISCUSSION AND CONCLUSION
This study describes a population pharmacokinetic model for pioglitazone in nondiabetic adults. Following oral administration of a single 15 mg dose, pioglitazone pharmacokinetic parameters were best described by a two-compartment model with first order absorption and elimination from the central compartment. A considerable amount of between-subject variability was present in pioglitazone CL/F (43%) and Q/F (130%) in the base model, and CYP2C8*3 proved to be the only significant covariate on pioglitazone CL/F and Q/F in the final model. Pioglitazone CL/F and Q/F were 52% and 286% higher, respectively, in carriers of the polymorphic CYP2C8*3 allele as compared with CYP2C8*1/*1 homozygotes. The inclusion of CYP2C8*3 as a covariate in the model reduced interindividual variability in CL/F and Q/F by 5.2% and 14%, respectively.
To the best of our knowledge, only a few pioglitazone population pharmacokinetic models have been published in the literature. Compared to a single compartment model, we found that the addition of a distribution compartment resulted in a significant improvement in data fit and a substantial reduction in the AIC (−133) and OFV (−136.6). In patients with renal or hepatic impairment, pioglitazone pharmacokinetics were best described by a two-compartment model with first-order elimination.
3) Our data are also consistent with a few healthy volunteer studies which showed that pioglitazone plasma concentrations declined in a biphasic manner, which suggests distribution compartments. 9, 15) In contrast, a population model of oral single-and multiple-dose pioglitazone pharmacokinetics in adolescents with type 2 diabetes showed that a one-compartment model was sufficient to describe the data. 16, 17) This difference between studies could be due to inherent physiologic differences between adolescents and adults and/or differences in PK sampling times between studies.
The population model in our study yielded mean pioglitazone parameter estimates that are consistent with previous reports showing that pioglitazone apparent oral clearance ranges from 1.72 to 4.17 L/h and volume of distribution ranges from 0.2 to 0.3 L/kg.
3) The K a estimate in the model was slightly higher than a previous report of 0.4 to 1.17 h −1 . 3) This difference in K a is most likely due to the limited number of time points that were sampled in the absorption phase of the plasma concentration-time profiles in our study.
In terms of covariate analysis, the CYP2C8*3 allele was the only covariate that significantly influenced CL/F and Q/F in the study. Specifically, pioglitazone CL/F was about 51% higher in carriers of the CYP2C8*3 allele as compared with CYP2C8*1 homozygotes. This finding is consistent with published reports of increased hepatic metabolism and decreased plasma exposure of thiazolidinediones (i.e., pioglitazone and rosiglitazone) in carriers of the CYP2C8*3 allele.
9,10,13) Based on in vitro data, it is hypothesized that the functional mechanism underlying this observation may be greater affinity of the CYP2C8*3 allele for cytochrome b5 and cytochrome P450 reductase.
18) Overall, we found 43% and 130% interindividual variability in CL/F and Q/F, respectively, in the population model. The high degree of interindividual variability associated with Q/F may be a result of different rates of blood flow between compartments, or the size and/or composition of the peripheral compartment (e.g., varying degrees of fat mass) between individuals. When the CYP2C8*3 polymorphism was included as a covariate on CL/F and Q/F, we observed a significant reduction in interindividual variability on these parameters. however, it is important to note that the reduction in variability was modest (i.e., −5.2% CL/F and −14% Q/F) which suggests that other, unaccounted for, genetic, demographic, or clinical variables may be impacting CL/F and Q/F in this healthy volunteer cohort. For example, the population analysis included only one subject with the CYP2C8*3/*3 genotype. Future pharmacokinetic studies with more CYP2C8*3 homozygotes may reveal a larger impact of CYP2C8 genetics on interindividual variability in pioglitazone CL/F. It is also important to note that these CYP2C8 genetic findings are most applicable to Caucasian individuals, as CYP2C8*3 is common in Caucasians (10 to 23%), but is rare in African and Asian populations. 19) Beyond CYP2C8*3, we did not identify any other covariates (e.g., sex, body weight, serum creatinine, liver function) that significantly impacted pioglitazone pharmacokinetics in the study population. Pioglitazone prescribing information states that mean pioglitazone plasma exposure is 60% higher in women than men, however no dose adjustment is recommended based on sex alone. 7) Although the findings in our study differ from what is reported in prescribing information, they are consistent with a report by Karim and colleagues, which showed no effect of sex or body weight on the pharmacokinetics of pioglitazone after oral administration in healthy volunteers. 20) These investigators also reported no differences in pioglitazone plasma exposure between Caucasians, Blacks, and hispanics. 20) Unfortunately, we could not assess the effects of race or ethnicity on pioglitazone disposition in the population given that all of the subjects were Caucasian. Compared with healthy volunteers, patients with type 2 diabetes are often older, have renal and/or liver impairment, and are overweight or obese. Data suggest that older age, renal impairment, and liver impairment do not have a significant impact on pioglitazone pharmacokinetics, and that the dose of pioglitazone does not need to be adjusted in these situations. 3, 7) In terms of body weight, a study reported that subjects weighing 50 to 123 kg (all with a body mass indices less than 35 kg/ m 2 ) showed no correlation between body weight and systemic exposure of pioglitazone. 20) Whether individuals with body weights greater the 123 kg, or body mass indices greater than 35 kg/m 2 , require higher doses of pioglitazone remains to be determined.
In terms of model performance, the pharmacokinetic parameters for the final model were estimated with good precision. The %RSE was less than 46% for all pharmacokinetic parameters. Furthermore, bootstrap analysis showed that the final model was stable and robust. The median parameter estimates obtained from bootstrap analyses were highly comparable to the point estimates obtained from the final selected models for pioglitazone. A visual predictive check also showed that the population pharmacokinetic model of pioglitazone replicates well the features of the data from which the models were built.
In conclusion, plasma pioglitazone pharmacokinetic parameters were best described by a two-compartment model with first order of absorption and elimination. CYP2C8*3 was the only covariate that significantly affected pioglitazone CL/F, Q/F, and interindividual variability in these parameters in this cohort of healthy, nondiabetic adults.
